Castle Biosciences Inc
NASDAQ:CSTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
S&P Global Inc
SWB:MHL
|
US |
Castle Biosciences Inc
Non-Reccuring Items
Castle Biosciences Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Castle Biosciences Inc
NASDAQ:CSTL
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Non-Reccuring Items
-$95m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
CVS Health Corp
NYSE:CVS
|
Non-Reccuring Items
-$5.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Non-Reccuring Items
-$1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Non-Reccuring Items
-$131.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-1%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Non-Reccuring Items
-$4.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
